<DOC>
	<DOCNO>NCT01700582</DOCNO>
	<brief_summary>The French National Cancer Institute ( INCa ) support 28 hospital platform network molecular testing cancer patient . These platform routinely assess panel biomarkers order speed access French cancer patient target therapy ( commercially available clinical trial ) . The objective BIOMARKERS-France study describe epidemiological , clinical molecular characteristic patient tumor assess impact analyze treatment ( ie bio-guided therapy ) well outcomes ( response rate , progression free overall survival ) .</brief_summary>
	<brief_title>French National Observatory Patients With Non-small Cell Lung ( NSCLC ) Molecular Testings</brief_title>
	<detailed_description>The French National Cancer Institute ( INCa ) support 28 hospital platform network molecular testing cancer patient . These platform routinely assess panel biomarkers order speed access French cancer patient target therapy ( commercially available clinical trial ) . Regarding stage IV non-squamous NSCLC patient , 7 biomarkers assess include activate EGFR mutation , EML4-ALK translocation EGFR T790M , KRAS , BRAF , HER2 PI3KCA mutation . In 2012 , 17 20,000 patient test platform network . The objective BIOMARKERS-France study describe epidemiological , clinical molecular characteristic patient tumor assess impact analyze treatment ( ie bio-guided therapy ) well outcomes ( response rate , progression free overall survival ) . This study collect , prospective way , data unique national cohort order guide future decision regard biomarker assessment ( type ? Number ? Methods ? Etc ) connexion research work currently ongoing France .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Advanced Nonsmall cell lung cancer ( NSLC ) Biomarkers analysis hospital platform Histology NSLC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>biomarkers</keyword>
	<keyword>EGFR</keyword>
	<keyword>KRAS</keyword>
	<keyword>ALK</keyword>
	<keyword>HER2</keyword>
	<keyword>PI3K</keyword>
	<keyword>BRAF</keyword>
</DOC>